By InvitationPhase 3

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

United States126 participantsStarted 2025-11-14

Plain-language summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Age range55 Years – 84 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The subject's LAR (or study partner/caregiver, if local regulations allow) must provide written informed consent.
✓. The subject must provide written (if capable) informed assent per local regulations
✓. Refrain from donating sperm, AND
✓. Either

✕. jeopardize the safe participation of the subject in this study; OR
✕. interfere with the conduct or interpretation of safety or efficacy evaluations in the study

Proportion of subjects who experience treatment-emergent adverse events (TEAEs)

Timeframe: 52 weeks

NCT IDNCT07095465

SponsorACADIA Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-02